 |
 |

The Economics of Therapeutic Advances
The Paradigm of Sympathetic Suppression in Chronic Heart Failure
Arch Intern Med. 1999;159:2634-2636.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
THE IMPACT of a newly introduced therapeutic approach is mostly determined by 2 facts: (1) it addresses a common condition that affects large numbers of people and defines their functional status and quality of life for long periods of time; (2) it is inexpensive and readily available not only to those who live in technologically advanced societies, but also to those who live in the developing countries, where most of the world's population resides. While death rates from other cardiovascular diseases are decreasing, the incidence of death rates from heart failure has been increasing in recent years. Several factors account for this trend, including, ironically, the successful management of inflammatory or ischemic heart disease, hypertension, and other conditions that lead to heart failure, as well as increasing life expectancy. Indeed, today, heart failure is estimated to affect about 5 million people in the United States, of whom more than 75% . . . [Full Text of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Using Measures of Disease Progression to Determine Therapeutic Effect: A Sirens' Song
Granger and McMurray
J Am Coll Cardiol 2006;48:434-437.
ABSTRACT
| FULL TEXT
A Dose of Our Own Medicine: Alternative Medicine, Conventional Medicine, and the Standards of Science
Morreim
J Law Med Ethics 2003;31:222-235.
|